(A) Scheme for the generation of Vil1CreIl1r1Δ/Δ mice. (B) Immunofluorescence analysis showing absence of IL-1R1 expression (red) in SI sections of Vil1CreIl1r1Δ/Δ as compared with Il1r1fl/fl mice. (C) FITC-dextran intestinal permeability assay in PBS-injected Il1r1fl/fl, LCWE-injected Il1r1fl/fl and LCWE-injected Vil1CreIl1r1Δ/Δ 24 h post-injection (n=7–10 per group). Data normalized to PBS controls. (D, E) Representative H&E staining of heart sections (D) and heart vessels inflammation score (E) of LCWE-injected Il1r1fl/fl and Vil1CreIl1r1Δ/Δ (n=14 per group). Scale bars: 500μm. (F) Representative pictures of abdominal area and H&E staining of abdominal aorta cross-section from LCWE-injected Il1r1fl/fl and Vil1CreIl1r1Δ/Δ. Scale bars: 200μm. (G) Measurement of maximal abdominal diameter of LCWE-injected Il1rl1fl/fl and Vil1CreIl1r1Δ/Δ (n=12–14 per group). (H) Representative H&E sections and immunostaining of CD31 (green) and IgA (red) in the heart coronary artery of LCWE-injected Il1r1fl/fl (1; non-obstructed and 2; obstructed coronary) and Vil1CreIl1r1Δ/Δ. Scale bars: 25μm. (I) H&E abdominal aorta cross sections staining and immunostaining of CD31 (green) and IgA (red) in the abdominal aorta of LCWE-injected Il1r1fl/fl. Scale bars: 10μm. (J) IgA immunofluorescence quantification in the heart and abdominal aorta of LCWE-injected Il1rl1fl/fl and Vil1CreIl1r1Δ/Δ (n=5 per group). Data are presented as mean ± s.e.m. *p<0.05,**p<0.01, ***p<0.001 by 1-way ANOVA with Bonferroni post-test (C) or two-tailed unpaired t test (E, G and J) and pooled from 2 to 4 independent experiments.